<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01667718</url>
  </required_header>
  <id_info>
    <org_study_id>rjkls2012011</org_study_id>
    <nct_id>NCT01667718</nct_id>
  </id_info>
  <brief_title>Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment</brief_title>
  <official_title>Levofloxacin-containing Therapy for Helicobacter Pylori Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and
      without Bismuth for H.pylori treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The success rate of the standard triple therapy for H. pylori infection is decreasing
      recently.Fluoroquinolone has been proposed to replace clarithromycin as an alternative in the
      treatment. However prevalence of H.pylori resistance to Levofloxacin has increased rapidly in
      our area. The purpose of this study is to observe the efficacy of 14 day Levofloxacin triple
      therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eradication rate of Helicobacter pylori</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Functional Dyspepsia</condition>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Levofloxacin-triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin-quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth</intervention_name>
    <description>Bismuth 220mg b.i.d for 2 weeks</description>
    <arm_group_label>Levofloxacin-quadruple therapy</arm_group_label>
    <other_name>Bismuth potassium citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole 30 mg b.i.d.for 2 weeks</description>
    <arm_group_label>Levofloxacin-triple therapy</arm_group_label>
    <arm_group_label>Levofloxacin-quadruple therapy</arm_group_label>
    <other_name>Proton Pump Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levoﬂoxacin</intervention_name>
    <description>Levoﬂoxacin 0.5 q.d. for 2 weeks</description>
    <arm_group_label>Levofloxacin-triple therapy</arm_group_label>
    <arm_group_label>Levofloxacin-quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin 1 g b.i.d. for 2 weeks</description>
    <arm_group_label>Levofloxacin-triple therapy</arm_group_label>
    <arm_group_label>Levofloxacin-quadruple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who presented with upper gastrointestinal symptoms and endoscopically proven
             H.pylori-positive functional dyspepsia and scarred peptic ulcer

        Exclusion Criteria:

          -  patients with peptic ulcer, previous H.pylori eradication therapy, previous gastric
             surgery, pregnancy, lactation, major systemic diseases, receipt of anti-secretory
             therapy, antibiotics or bismuth in the preceding 4 weeks, or allergy to any one of the
             medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao-Tong University School of Medicine Renji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Jiao-Tong University School of Medicine Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Dr. HONG LU</investigator_full_name>
    <investigator_title>Professor of GI Division</investigator_title>
  </responsible_party>
  <keyword>eradication</keyword>
  <keyword>helicobacter pylori</keyword>
  <keyword>bismuth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

